Sugi Predict

Sugi Predict / Compounds / SCHEMBL724453

SCHEMBL724453

SCHEMBL724453

COc1cc(C(=O)c2c[nH]c(-c3ccc4[nH]c(C(=O)c5cc(OC)c(OC)c(OC)c5)cc4c3)n2)cc(OC)c1OC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 2/20 0.52
▸ PDGFRA P16234 2/20 0.52
▸ EGFR P00533 1/20 0.50
▸ TUBB1 Q9H4B7 9/20 0.46
▸ TUBB4A P04350 8/20 0.46
▸ TUBB P07437 8/20 0.46
▸ TUBA3C P0DPH7 8/20 0.46
▸ TUBA1B P68363 8/20 0.46
▸ TUBA4A P68366 8/20 0.46
▸ TUBB4B P68371 8/20 0.46
▸ TUBB3 Q13509 8/20 0.46
▸ TUBB2A Q13885 8/20 0.46
▸ TUBB8 Q3ZCM7 8/20 0.46
▸ TUBA3E Q6PEY2 8/20 0.46
▸ TUBA1A Q71U36 8/20 0.46
▸ TUBA1C Q9BQE3 8/20 0.46
▸ TUBB6 Q9BUF5 8/20 0.46
▸ TUBB2B Q9BVA1 8/20 0.46
▸ ABCB1 P08183 1/20 0.43
▸ MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15909614 0.92 PDGFRB (0.47) PDGFRBPDGFRAEGFRTUBB1TUBB4A
SCHEMBL31247308 0.85 EGFR (0.68) EGFRTUBB1TUBB4ATUBBTUBA3C
SCHEMBL4427854 0.85 EGFR (0.68) EGFRTUBB1TUBB4ATUBBTUBA3C
SCHEMBL28523891 0.84 EGFR (0.51) EGFRTUBB1TUBB4ATUBBTUBA3C
SCHEMBL726093 0.83 EGFR (0.51) EGFRTUBB1TUBB4ATUBBTUBA3C
SCHEMBL20850791 0.83 PDGFRB (0.53) PDGFRBPDGFRAEGFRTUBB1TUBB4A
SCHEMBL723242 0.82 EGFR (0.50) EGFRTUBB1TUBB4ATUBBTUBA3C
SCHEMBL724651 0.81 TUBB4A (0.49) EGFRTUBB1TUBB4ATUBBTUBA3C
SCHEMBL723931 0.81 TUBB1 (0.57) PDGFRBEGFRTUBB1TUBB4ATUBB
SCHEMBL725053 0.81 PDGFRB (0.50) PDGFRBEGFRTUBB1TUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 — — US disclosed
CN-119548495-A Use of (substituted 1H-imidazol-4-yl) (3, 4, 5-trimethoxyphenyl) methanones for the treatment of coronaviruses 维鲁公司 2025-03-04 — — CN disclosed
EP-4504183-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS Veru Inc. (US) 2025-02-12 — — EP disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 — — US disclosed
CN-118984703-A Methods of treating influenza and poxvirus infections 维鲁公司 2024-11-19 — — CN disclosed
US-20240180879-A1 METHODS OF TREATING INFLAMMATION VERU INC. (US) 2024-06-06 — — US disclosed
EP-4320151-A1 METHODS OF TREATING INFLAMMATION Veru Inc. (US) 2024-02-14 — — EP disclosed
CN-117396505-A Methods of treating inflammation 维鲁公司 2024-01-12 — — CN disclosed
WO-2023196632-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 — — WO disclosed
US-20230321045-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 — — US disclosed
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-08-01 — — US disclosed
EP-2608671-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-07-03 — — EP disclosed
EP-2542081-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-01-09 — — EP disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 — — US disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 — — US disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 — — US disclosed
WO-2012027481-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2012-03-01 — — WO disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 — — US disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 — — US disclosed
WO-2011109059-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2011-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 PDGFRB 2557/4885PDGFRA 3483/4885EGFR 964/4885
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 PDGFRB 2557/4885PDGFRA 3483/4885EGFR 964/4885
US-20240180879-A1 METHODS OF TREATING INFLAMMATION IL1B, PYCARD, TUBB1 PDGFRB 3698/4885PDGFRA 4277/4885EGFR 4826/4885
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 PDGFRB 2557/4885PDGFRA 3483/4885EGFR 964/4885
US-20230321045-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS TUBB3, TUBB1, TUBB PDGFRB 3983/4885PDGFRA 4313/4885EGFR 3966/4885
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 PDGFRB 2557/4885PDGFRA 3483/4885EGFR 964/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 PDGFRB 2557/4885PDGFRA 3483/4885EGFR 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.